Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

Neurology. 2006 Aug 8;67(3):511-3. doi: 10.1212/01.wnl.0000231137.24467.aa. Epub 2006 Jun 14.


The authors studied the safety and tolerability of subcutaneous interferon beta-1a at different doses in 24 children with clinically definite multiple sclerosis. After a mean treatment period of 44 months, interferon beta-1a was well tolerated in 22 patients, although two experienced possible serious adverse events. Although effectiveness cannot be inferred from this study, the authors did observe a significant reduction in the relapse rate at 22 mug, three times weekly, in the relapsing-remitting subgroup.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Age of Onset
  • Child
  • Female
  • Humans
  • Immunotherapy
  • Interferon beta-1a
  • Interferon-beta / immunology
  • Interferon-beta / therapeutic use*
  • Male
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Prospective Studies
  • Treatment Outcome


  • Interferon-beta
  • Interferon beta-1a